Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s stock price crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $3.87 and traded as high as $3.89. Armata Pharmaceuticals shares last traded at $3.89, with a volume of 50,548 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Armata Pharmaceuticals in a research note on Tuesday, September 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Stock Up 3.7%

The firm’s fifty day moving average price is $3.87 and its 200 day moving average price is $6.87. The stock has a market cap of $144.63 million, a PE ratio of -0.51 and a beta of 1.54.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.17. The firm had revenue of $2.51 million during the quarter, compared to analyst estimates of $0.40 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. As a group, analysts anticipate that Armata Pharmaceuticals, Inc. will post 0.50 earnings per share for the current fiscal year.

Institutional Trading of Armata Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Madison Asset Management LLC purchased a new stake in Armata Pharmaceuticals in the 1st quarter worth $21,583,000. BlackRock Inc. bought a new position in shares of Armata Pharmaceuticals during the 2nd quarter valued at about $3,629,000. Sei Investments Co. purchased a new position in shares of Armata Pharmaceuticals during the first quarter valued at about $760,000. Bank of New York Mellon Corp purchased a new position in shares of Armata Pharmaceuticals during the second quarter valued at about $193,000. Finally, Nisa Investment Advisors LLC purchased a new position in shares of Armata Pharmaceuticals during the third quarter valued at about $50,000. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics. The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus .